39
Participants
Start Date
November 21, 2019
Primary Completion Date
July 29, 2024
Study Completion Date
September 24, 2026
Biopsy Procedure
Undergo tumor biopsy
Biospecimen Collection
Undergo collection of blood samples
Computed Tomography
Undergo CT
Copanlisib Hydrochloride
Given IV
Durvalumab
Given IV
Echocardiography Test
Undergo ECHO
Magnetic Resonance Imaging
Undergo MRI
Olaparib
Given PO
X-Ray Imaging
Undergo x-ray
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Northwestern University, Chicago
M D Anderson Cancer Center, Houston
University of Texas Health Science Center at San Antonio, San Antonio
University of Texas at Austin, Austin
UCHealth University of Colorado Hospital, Aurora
Keck Medicine of USC Koreatown, Los Angeles
Los Angeles General Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
Keck Medicine of USC Buena Park, Buena Park
Keck Medical Center of USC Pasadena, Pasadena
USC Norris Oncology/Hematology-Newport Beach, Newport Beach
Brigham and Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
University of Texas Medical Branch, Galveston
National Cancer Institute (NCI)
NIH